SARS-CoV-2 Antibody Testing Linked to Increase in First-Time Blood Donors
Antibody testing after the early stages of the SARS-CoV-2 pandemic has significantly increased in the proportion of first-time blood donors.
All articles by Jonathan Goodman, MPhil
Prevalence of Iron Toxicity in Lower-Risk Myelodysplastic Syndromes
Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.
Classical Hodgkin Lymphoma: Patients Face Unnecessary Risk of Death Unrelated to Lymphoma
Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.
Ibrutinib Effectiveness in Symptomatic, Previously Treated Waldenström Macroglobulinemia
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Combined Venetoclax, Obinutuzumab vs Chlorambucil, Obinutuzumab for Chronic Lymphocytic Leukemia
Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.
Quercetin May Induce Autophagy in Myelodysplastic Bone Marrow, Mouse Model Suggests
A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.
Follicular Lymphoma: Interactions With Surrounding Cells to Identify Therapeutic Targets
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Venetoclax With a Hypomethylating Agent Effective in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukemia
Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.
Low Bone Mass Common in Patients With Hemophilia
Investigators assessed whether there was a link between low bone mineral density, 25(OH)D concentrations, and bone turnover markers in hemophilia.
-
Loading...
-
Loading...
Next post in Bleeding Disorders
